BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity. Over the past few...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

Checkmate raised $85 million in a series C round to advance lead program CMP-001 across a range of cancer indications. Longitude Capital and Novo Holdings A/S led the round for Cambridge, Mass.-based Checkmate Pharmaceuticals Inc.,...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of...
BioCentury | May 22, 2020
Politics, Policy & Law

Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...
BioCentury | May 21, 2020
Product Development

With AZ deal, Operation Warp Speed takes first step to train guns on coronavirus

Operation Warp Speed, along with its promises and dangers, is coming into sharp focus. Its investment of up to $1.2 billion in a COVID-19 vaccine candidate is testimony to the risks it is prepared to...
BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

It’s not yet clear how deep the economic scars will be for biotechs from this crisis. Some will surely suffer. But VCs and pharmas see an opportunity for the industry to emerge stronger, given that...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BioCentury | Mar 26, 2020
Finance

SutroVax heading to clinic with potential competitor to Pfizer’s Prevnar 13

With its new $110 million series D round, SutroVax is preparing for its first clinical trial that could test its 24-valent pneumonia vaccine against Prevnar 13 -- or a next-generation version. RA Capital and Janus...
BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

The heavy reliance of Italy’s biotech sector on academic labs and angel investors could result in many companies facing existential risk during the coronavirus outbreak. If they can hang on, the silver lining is that...
Items per page:
1 - 10 of 102
BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity. Over the past few...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

Checkmate raised $85 million in a series C round to advance lead program CMP-001 across a range of cancer indications. Longitude Capital and Novo Holdings A/S led the round for Cambridge, Mass.-based Checkmate Pharmaceuticals Inc.,...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of...
BioCentury | May 22, 2020
Politics, Policy & Law

Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER

In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation...
BioCentury | May 21, 2020
Product Development

With AZ deal, Operation Warp Speed takes first step to train guns on coronavirus

Operation Warp Speed, along with its promises and dangers, is coming into sharp focus. Its investment of up to $1.2 billion in a COVID-19 vaccine candidate is testimony to the risks it is prepared to...
BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

It’s not yet clear how deep the economic scars will be for biotechs from this crisis. Some will surely suffer. But VCs and pharmas see an opportunity for the industry to emerge stronger, given that...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BioCentury | Mar 26, 2020
Finance

SutroVax heading to clinic with potential competitor to Pfizer’s Prevnar 13

With its new $110 million series D round, SutroVax is preparing for its first clinical trial that could test its 24-valent pneumonia vaccine against Prevnar 13 -- or a next-generation version. RA Capital and Janus...
BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

The heavy reliance of Italy’s biotech sector on academic labs and angel investors could result in many companies facing existential risk during the coronavirus outbreak. If they can hang on, the silver lining is that...
Items per page:
1 - 10 of 102